Delivery of an anti‐transthyretin Nanobody to the brain through intranasal administration reveals transthyretin expression and secretion by motor neurons

This work was supported by FEDER funds through the Operational Competitiveness Programme – COMPETE, by national funding from the Portuguese Foundation for Science and Technology (FCT) under the project PEst-C/SAU/LA0001/2011, QREN Brainiac 13141 and a post-doctoral fellowship (SFRH/BPD/84178/2012) to Joao Gomes. The authors acknowledge Paul Moreira for support in recombinant protein production and Paula Gon©calves, for tissue processing. The authors of the manuscript have the following potential competing interest: IC, HS, PV and, AW (left in 04/2012) were employees of ABLYNX at the time of work development. The other authors have no conflict of interests. The anti-TTR Nanobody discovery and characterization, as well as the quantification of Nanobodies in brain samples was performed by ABLYNX, whereas Nanobody delivery, tissue imaging, biochemistry processing as well as cellular cultures and data processing was performed by IBMC.